Literature DB >> 18930358

Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.

Min Yao1, Russell B Smith, Henry T Hoffman, Gerry F Funk, Minggen Lu, Yusuf Menda, Michael M Graham, John M Buatti.   

Abstract

PURPOSE: To determine the accuracy and prognostic significance of post-treatment [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) in head-and-neck squamous cell carcinoma after radiotherapy (RT). METHODS AND MATERIALS: This was a retrospective study of 188 patients with head-and-neck squamous cell carcinoma who had undergone FDG-PET within 12 months after completing RT. All living patients had >/=1 year of follow-up after FDG-PET. All patients had undergone intensity-modulated RT, 128 with definitive and 60 with postoperative intensity-modulated RT.
RESULTS: For all patients, the median follow-up after RT completion was 32.6 months and after FDG-PET was 29.2 months. For the neck, 171 patients had negative FDG-PET findings. Of these results, two were falsely negative. Seventeen patients had positive FDG-PET findings, of which 12 were true-positive findings. The sensitivity, specificity, positive predictive value, and negative predictive value for FDG-PET in the assessment of the treatment response in the neck was 86%, 97%, 71%, and 99%, respectively. For the primary site, 151 patients had negative FDG-PET findings, of which two were falsely negative. Thirty-seven patients had positive FDG-PET findings, of which 12 were true-positive findings. The sensitivity, specificity, positive predictive value, and negative predictive value for FDG-PET in the assessment of the treatment response in the primary site was 86%, 86%, 32.4%, and 98.7%, respectively. Patients with positive post-RT PET findings had significantly worse 3-year overall survival and disease-free survival.
CONCLUSION: The results of our study have shown that the findings of post-RT FDG-PET have a high negative predictive value and are a significant prognostic factor. It can provide guidance for the management of head-and-neck cancer after definitive treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930358     DOI: 10.1016/j.ijrobp.2008.07.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Thomas Bird; Sally Barrington; Selvam Thavaraj; Jean-Pierre Jeannon; Andrew Lyons; Richard Oakley; Ricard Simo; Mary Lei; Teresa Guerrero Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-28       Impact factor: 9.236

Review 3.  Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.

Authors:  P M Price; M M Green
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

4.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

5.  Sonographic examination of the neck after definitive radiotherapy for node-positive oropharyngeal cancer.

Authors:  S S Yom; A S Garden; G A Staerkel; L E Ginsberg; W H Morrison; E M Sturgis; D I Rosenthal; J N Myers; B S Edeiken-Monroe
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-14       Impact factor: 3.825

Review 6.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

Review 7.  Image-based biomarkers in clinical practice.

Authors:  John E Bayouth; Thomas L Casavant; Michael M Graham; Milan Sonka; Manickam Muruganandham; John M Buatti
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 8.  PET/CT in head and neck cancer: an update.

Authors:  Roland Hustinx; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

9.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.